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Key Message
Pulmonary lipiodol embolism is a fatal but pre-
ventable complication of transcatheter arterial
chemoembolization.
Introduction
Transcatheter arterial chemoembolization (TACE)
has become an effective alternative treatment strat-
egy for patients with inoperable hepatocellular
carcinoma (HCC). Although TACE is relatively
safe, pulmonary lipiodol embolism is a rare and
potentially fatal complication which is often not
anticipated by physicians.
1 About 14 patients
with pulmonary lipiodol embolism progressing
to respiratory distress were reported in previous
literature. Here, we report a patient with HCC
who survived a severe pulmonary lipiodol embo-
lism requiring mechanical ventilatorysupport and
uneventfully received the second course of TACE.
In this article, we sum previous literature and have
discussed the possible pathophysiological mech-
anism underlying this complication and risk
factors for its development.
Case history
A 76-year-old man, weighing 65 kgs and an alco-
holic drinker who consumed at least 500 mL of
whiskey per day, was diagnosed with a hepatic
tumor by abdominal sonography during a
routine health check-up. A triphasic helical com-
puted tomography (CT) scan revealed this
hepatic tumor to be 14.5 × 8.1 cm in size over seg-
ments 4, 7 and 8, with global enhancement in the
hepatic arterial (HA) phase and contrast
washout in the portal venous (PV) phase. His
serum α-fetal protein level was 9.57 ng/mL.
Angiography of the celiac, common hepatic, and
superior mesenteric arteries showed prominent
arteriovenous (A V) shunting due to early venous
drainage into the middle hepatic vein and the
right atrium. TACE was performed for this inoper-
able HCC via the right and left hepatic arteries. A
total of lipiodol 40 mL, adriamycin 40 mg, and
Gelfoam ﬁne particles were injected. Unfortu-
nately, the patient felt dyspneic immediately
after TACE and his oxygen saturation recorded
by pulse oximetry (SpO2) fell to 90% despite the
use of a non-rebreathing mask. A chest radiograph
showed diffuse bilateral air-space consolidations
with a normal heart size. Within 30 minutes, he
was intubated due to severe hypoxic respiratory
failure. His PaO2/FiO2 ratio was 53.3 and serum
D-dimer level 15.64 μg/mL. His right internal
jugular venous pressure was below 6 mmHg.
Chest CT without contrast enhancement revealed
retention of radiopaque lipiodol not only within
the hepatic tumor, but also in the dependent por-
tions of both lungs, especially on the right lower
lung lobe (Figure 1). He underwent mechanical
ventilation with a protective ventilatory strategy.
Methylprednisolone 40 mg was administered
every six hours. The lower molecular weight
heparin (LMWH), enoxaparin, was given at a
dose of 1 mg/kg for a total of two days. His
PaO2/FiO2 ratio improved dramatically to more
than 250 within two days and was liberated from
mechanical ventilation at post-TACE day 5. The
follow-up chest radiograph revealed complete
resolution of the bilateral pulmonary inﬁltrates
in three weeks. He underwent TACE again 27
days after the ﬁrst course using the same injection
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1routes but at a reduced dose of lipiodol (10 mL).
Before injection, the A V shunt was still present
but the bypass ﬂow was less prominent than that
shown in the previous angiograph. The procedure
was uneventful. He was discharged home in a
stable condition and continued to be followed up
at our outpatient clinic.
Discussion
Pulmonary lipiodol embolism, ﬁrst reported by
Samejima et al. in 1990,
2 is attributed to pulmonary
arterial occlusion by iodized oil, which is injected
into the hepatic arteryand bypassed into the lungs
through the normal hepatic vasculature or
through an A V shunt. Although 23% of asympto-
matic patients had abnormalities on pulmonary
perfusion scans after TACE,
3 the development of
respiratory symptoms is uncommon. The inci-
dence of symptomatic pulmonary lipiodol embo-
lism after TACE ranged between 0.05–1.8%.
1,4
These results conﬁrmed the speculation that
most pulmonary complications of TACE improve
or resolve spontaneously.
The most likely mechanism of symptomatic
pulmonary injury is a high concentration of
unbound free fatty acids resulting from break-
down of oil microemboli, which might lead to
pulmonary capillary leakage and non-cardiogenic
pulmonary oedema.
4 A summary of the case
Table 1
Summary of previous case reports for pulmonary lipiodol embolism after TACE in patients with primary liver cancer
Reference Patient No./
Sex/Age
(years)
Cancer type Maximal
tumor
size (cm)
TACE Method Period of
symptom
onset (days)
Total
recovery
period (days)
Outcome
LO
(ml)
C/T 
(mg)
11 /NM/NM PLC NM 25 NM 0.5 – E
22 /M/75 HCC NM 8 40 0.04 12 S
43 /M/44 HCC 17 40 60 4 28 S
44 /M/56 HCC 18 30 50 5 14 S
45 /F/31 HCC 20 30 50 2 21 S
46 /M/61 HCC 18 26 50 4 – E
47 /M/57 HCC 20 25 55 2 14 S
48 /M/55 HCC 14 22 50 2 10 S
10 9/NM/NM Hepatoblastoma NM 14 NM 0 NM NM
11 10/M/27 HCC 10 10 8 4 – E
11 11/M/63 HCC 15 17 13 1 14 S
12 12/F/81 HCC 14 15 NM 4 14 S
13 13/F/7 HCC 11 10 NM 0.04 – E
Our patient 14/M/76 HCC 14 40 40 0 21 S
NM= no mentioned in articles, TACE = transcatheter arterial chemoembolization, E=expired, S =survival, M =male, F =
female, HCC= hepatocellular carcinoma, PLC =primary liver cancer, LO= lipiodol, C/T= chemotherapy
Chemotherapy includes adriamycin, cisplatin, or doxorubicin hydrochloride
Figure 1
Chest CT scan after TACE without contrast
enhancement revealed high-density lipiodol
deposition in the dependent part of the bilateral
upper and lower lung ﬁeld (arrow)
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2reports published in literature is shown in Table 1.
Among patients who survived these episodes,
there was a signiﬁcant correlation (r =0.78, p =
0.013), between the amount of lipiodol injected
and the duration of patient recovery, which is an
indicator of the severity of lung injury (Figure 2).
A number of risk factors for pulmonary lipio-
dol embolism after TACE including the dose of
iodized oil injected, the presence of an A V shunt,
and trans-inferior phrenic artery (IPA) emboliza-
tion.
4,5 Among these factors, the amount of
iodized oil injected was the most important,
especially when more than 20 mL of iodized oil
was used.
4 In our case, the secondary course of
TACE was uneventful after reducing the dose of
lipiodol and existing a smaller A V shunting.
As for reducing the degree of A V shunting, suc-
cessful experience by temporary balloon occlusion
of hepatic vein branch with A V shunts
6 in HCC
patients with marked A V shunting was published.
Embolization of A V shunting with polyvinyl
alcohol, gelatine sponges, or coils may be an
alternative strategy.
7,8 However, if A V shunting is
refractory and severe after above-mentioned strat-
egies, TACE is contraindicated.
Similar to fat embolism syndrome, no therapy
has been shown to be effective for pulmonary
lipiodol embolism. Anecdotal success has been
achieved with treatments including oxygenation,
high-dose methylprednisolone, heparin, and posi-
tive end-expiratory pressure (PEEP).
9 In this
patient, his oxygenation responded dramatically
after using a protective ventilatory strategy,
methylprednisolone, and LMWH. Corticosteroids
can limit local accumulation of free fatty acids,
inhibit complement-mediated leukocyte aggrega-
tion, and block further cytokine storm. LMWH is
beneﬁcial in counteracting blood cell aggregation
to prevent further arterial occlusion. These man-
agements may facilitate recovery of such fulmi-
nant pulmonary lipiodol embolism with ARDS.
In conclusion, pulmonary lipiodol embolism
can be a serious complication after TACE. Risk
factors of this complication may include the dose
of iodized oil injected, the presence of A V shunt-
ing, and trans-IPA embolization. There is a signiﬁ-
cant correlation between the amount of lipiodol
and clinical severity of pulmonary injury. Our
experience from this case suggests that this com-
plication could be prevented by limiting the dose
of lipiodol injected and by reducing the degree
of A V shunting. Our treatment strategies may
also provide insights into optimal management
of this life-threatening complication.
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